Drug ID:Drug189
Drug Name:Cimetidine
CID:2756
DrugBank ID:DB00501
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT05020184, , NCT05365451, , NCT04862585, , NCT06056583, , NCT03307252, , NCT03380455, , NCT04493931, , NCT01010698, , NCT04018131, , NCT03618316, , NCT02157376, , NCT01757275, , NCT02555852, , NCT02202512, , NCT00515073, , NCT02172417, , NCT00002733, , NCT00800280, , NCT00002092
Molecular Formula:C10H16N6S
Molecular Weight:252.34 g/mol
Isomeric SMILES:CC1=C(N=CN1)CSCCNC(=NC)NC#N
Synonyms:cimetidine; 51481-61-9; Ulcedin; Acinil; Dyspamet; Gastromet; Tametin; Ulcimet; Cimal; Ulcomedina
Phase 0: 1
Phase 1: 11
Phase 2: 4
Phase 3: 5
Phase 4: 3
Description:A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. [PubChem]

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1315 2756 Cimetidine 1565 CYP2D6 Homo sapiens (human) None
dt1316 2756 Cimetidine 3274 HRH2 Homo sapiens (human) None
dt1317 2756 Cimetidine 3274 HRH2 Homo sapiens (human) Histamine H2 receptor antagonist
dt1318 2756 Cimetidine 6582 SLC22A2 Homo sapiens (human) None
dt1319 2756 Cimetidine 5243 ABCB1 Homo sapiens (human) Substrate|Inducer
dt1320 2756 Cimetidine 6582 SLC22A2 Homo sapiens (human) Substrate|Inhibitor
dt1321 2756 Cimetidine 6580 SLC22A1 Homo sapiens (human) Substrate|Inhibitor
dt1322 2756 Cimetidine 6581 SLC22A3 Homo sapiens (human) Substrate|Inhibitor
dt1323 2756 Cimetidine 6584 SLC22A5 Homo sapiens (human) Inhibitor
dt1324 2756 Cimetidine 9356 SLC22A6 Homo sapiens (human) Substrate|Inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
No data available

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Cimetidine and Clobenpropit Attenuate Inflammation-Associated Colorectal Carcin…

PMID: 26907350
Year: 2016
Relationship Type: Association Score: 6.3

Histamine and histamine receptors (Hrhs) have been identified as critical molecules during inflammation and carcinogenesis. This study was conducted …

View Details